Recently, I was approached by a colleague who had seen a patient with type 1 diabetes using a glucagon-like peptide-1 receptor agonist in combination with basal bolus insulin to manage their glucose levels.
In a small randomized study, this dietary approach was associated with reduced insulin doses and treatment costs, without restricting calories or carbohydrates.
Study examines the association between initiation of GLP-1 RAs versus dipeptidyl peptidase-4 inhibitors and fragility fracture risk in adults with type 2 diabetes.
Dr. Robert Dickson presents a case involving a patient who came to his clinic asking for ‘just a cream,’ but discovered a far more serious issue upon examination.
